论文部分内容阅读
根据祖国医学活血化瘀治则,我院选用“冠通四号”方对心血管疾患患者进行治疗,经较长时间的临床实践,总结出“冠通四号”有一定疗效。又经实验研究,揭示该方除有扩张血管、促进梗塞区周围血管增生等作用外,我们发现尚有减少冠心病人血小板聚集的效应。为进一步检验“冠通四号”是否可降低心肌内血管中的血小板聚集作用,以及使血小板聚集性降低的体外实验与在体实验结果是否一致,我们用 Haft 冰水应激动物模型诱发血小板聚集,心脏取血做血小板聚集型比例观
According to the Chinese medicine for promoting blood circulation and resolving phlegm, our hospital chose “Guantong No. 4” to treat patients with cardiovascular diseases. After a long period of clinical practice, we concluded that Guantong No. 4 had a certain effect. Through experimental research, it was revealed that in addition to its role in dilating blood vessels and promoting perivascular hyperplasia in the infarct region, we found that there are still effects of reducing platelet aggregation in patients with coronary heart disease. To further examine whether “Guan Tong IV” can reduce platelet aggregation in blood vessels in the myocardium, and whether the in vitro test for reducing platelet aggregation is consistent with the in vivo test results, we used the Haft ice water stress animal model to induce platelet aggregation. , heart blood for platelet aggregation type ratio view